<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T01:35:05Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/18679" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/18679</identifier><datestamp>2026-09-24T05:01:15Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Chan, Anthony</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">Chang, Gabriela</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Medical Sciences (Blood and Cardiovascular)</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2016-01-05T20:04:34Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2016-01-05T20:04:34Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2016</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/18679</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/10236</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">Unfractionated heparin (UFH) and low molecular weight heparin (LMWH) are&#xd;
commonly used anticoagulants to treat thrombotic diseases. However, these anticoagulants are&#xd;
associated with some limitations such as increased bleeding, variable dose response, and the&#xd;
necessity for frequent monitoring. This led to the development of the antithrombin-heparin&#xd;
covalent complex (ATH) which has been shown to overcome many of these limitations.&#xd;
Numerous past studies have proven ATH to be a better anticoagulant in comparison to UFH.&#xd;
More recent studies aimed at studying its interaction with the fibrinolytic pathway. It was&#xd;
observed that ATH inhibited free and fibrin bound plasmin (Pn), the main serine protease of&#xd;
fibrinolysis. As well, the rates of Pn generation on fibrin clots decreased in the presence of ATH.&#xd;
These studies were conducted in purified systems and did not elucidate the interaction of ATH&#xd;
with Pn in the presence of its natural inhibitors, α2-macroglobulin (α2-M) and α2-antiplasmin&#xd;
(α2-AP). Thus, this study focuses on analyzing the effects of ATH in comparison to UFH and&#xd;
LMWH on Pn generation in plasma, to allow for a better understanding of such mechanisms&#xd;
under more physiological conditions. In comparison to the absence of anticoagulants, total Pn&#xd;
generated decreased in the presence of 0.7 U/ml of UFH or ATH and 2.1 U/ml of ATH. This&#xd;
confirms previous in vitro studies in which UFH + AT and ATH can inhibit Pn activity. In&#xd;
addition, quantified Pn bound α2-M complexes showed a reduction at 0.7 U/ml of ATH&#xd;
suggesting that ATH may be able to compete with α2-M for Pn. However, the amount of&#xd;
quantified Pn bound α2-AP complexes were not affected as α2-AP is a much faster inhibitor of&#xd;
Pn. It was noted that LMWH did not affect Pn generation. As a result, this study adds to our&#xd;
understanding of ATH mechanisms of action and aids in its development for clinical use.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degreetype" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Master of Science (MSc)</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">en</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">Inhibition of Plasmin Generation in Plasma by Heparin, Low Molecular Weight Heparin and a Covalent Antithrombin-Heparin Complex (ATH)</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>